微創醫療(0853.HK) | 集結令在線分享

作為港股明星的微創醫療被戲稱為能“產生很多上市公司的上市公司”,去年以來表現強勁,近期股價更是頻創新高,市值超過千億港元。無論一級市場還是二級市場都看好的微創醫療,究竟有何魅力?
本次集結令,我們邀請到了湧容資產的研究員孟昱,給大家帶來分享:微創醫療(0853.HK)。

會議時間:2021/4/28(週三)19:00-20:30
會議主題:微創醫療(0853.HK)
主講嘉賓:孟昱(湧容資產研究員)
參會方式:掃碼聯繫客服

長按識別二維碼,添加客服
l 本活動屬於格隆匯付費投研欄目【集結令】訂閲用户權益
l 諮詢客服可獲取免費限量參會資格
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.